Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Stepwise activation of a class C GPCR begins with millisecond dimer rearrangement.

Grushevskyi EO, Kukaj T, Schmauder R, Bock A, Zabel U, Schwabe T, Benndorf K, Lohse MJ.

Proc Natl Acad Sci U S A. 2019 May 14;116(20):10150-10155. doi: 10.1073/pnas.1900261116. Epub 2019 Apr 25.

2.

A universal bioluminescence resonance energy transfer sensor design enables high-sensitivity screening of GPCR activation dynamics.

Schihada H, Vandenabeele S, Zabel U, Frank M, Lohse MJ, Maiellaro I.

Commun Biol. 2018 Aug 7;1:105. doi: 10.1038/s42003-018-0072-0. eCollection 2018.

3.

Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization.

Treppiedi D, Jobin ML, Peverelli E, Giardino E, Sungkaworn T, Zabel U, Arosio M, Spada A, Mantovani G, Calebiro D.

Endocrinology. 2018 Aug 1;159(8):2953-2965. doi: 10.1210/en.2018-00368.

PMID:
29931263
4.

FRET Studies of Quinolone-Based Bitopic Ligands and Their Structural Analogues at the Muscarinic M1 Receptor.

Messerer R, Kauk M, Volpato D, Alonso Canizal MC, Klöckner J, Zabel U, Nuber S, Hoffmann C, Holzgrabe U.

ACS Chem Biol. 2017 Mar 17;12(3):833-843. doi: 10.1021/acschembio.6b00828. Epub 2017 Feb 6.

PMID:
28117571
5.

β-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle.

Nuber S, Zabel U, Lorenz K, Nuber A, Milligan G, Tobin AB, Lohse MJ, Hoffmann C.

Nature. 2016 Mar 31;531(7596):661-4. doi: 10.1038/nature17198. Epub 2016 Mar 23.

6.

PKA catalytic subunit mutations in adrenocortical Cushing's adenoma impair association with the regulatory subunit.

Calebiro D, Hannawacker A, Lyga S, Bathon K, Zabel U, Ronchi C, Beuschlein F, Reincke M, Lorenz K, Allolio B, Kisker C, Fassnacht M, Lohse MJ.

Nat Commun. 2014 Dec 5;5:5680. doi: 10.1038/ncomms6680.

PMID:
25477193
7.

Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome.

Beuschlein F, Fassnacht M, Assié G, Calebiro D, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T, Barreau O, Vezzosi D, Rizk-Rabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro A, Zuffardi O, Kisker C, Diener S, Meitinger T, Lohse MJ, Reincke M, Bertherat J, Strom TM, Allolio B.

N Engl J Med. 2014 Mar 13;370(11):1019-28. doi: 10.1056/NEJMoa1310359. Epub 2014 Feb 26.

8.

Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization.

Calebiro D, Rieken F, Wagner J, Sungkaworn T, Zabel U, Borzi A, Cocucci E, Zürn A, Lohse MJ.

Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):743-8. doi: 10.1073/pnas.1205798110. Epub 2012 Dec 24.

9.

Sequential inter- and intrasubunit rearrangements during activation of dimeric metabotropic glutamate receptor 1.

Hlavackova V, Zabel U, Frankova D, Bätz J, Hoffmann C, Prezeau L, Pin JP, Blahos J, Lohse MJ.

Sci Signal. 2012 Aug 14;5(237):ra59. doi: 10.1126/scisignal.2002720.

10.

[Appreciating the multiplicity of residents].

Zabel U.

Pflege Z. 2012 Apr;65(4):212-4. German. No abstract available.

PMID:
22571041
11.

Comparison of the activation kinetics of the M3 acetylcholine receptor and a constitutively active mutant receptor in living cells.

Hoffmann C, Nuber S, Zabel U, Ziegler N, Winkler C, Hein P, Berlot CH, Bünemann M, Lohse MJ.

Mol Pharmacol. 2012 Aug;82(2):236-45. doi: 10.1124/mol.112.077578. Epub 2012 May 7.

PMID:
22564786
12.

FRET-based sensors for the human M1-, M3-, and M5-acetylcholine receptors.

Ziegler N, Bätz J, Zabel U, Lohse MJ, Hoffmann C.

Bioorg Med Chem. 2011 Feb 1;19(3):1048-54. doi: 10.1016/j.bmc.2010.07.060. Epub 2010 Jul 30.

PMID:
20716489
13.

Site-specific, orthogonal labeling of proteins in intact cells with two small biarsenical fluorophores.

Zürn A, Klenk C, Zabel U, Reiner S, Lohse MJ, Hoffmann C.

Bioconjug Chem. 2010 May 19;21(5):853-9. doi: 10.1021/bc900394j.

PMID:
20429545
14.

Fluorescence resonance energy transfer analysis of alpha 2a-adrenergic receptor activation reveals distinct agonist-specific conformational changes.

Zürn A, Zabel U, Vilardaga JP, Schindelin H, Lohse MJ, Hoffmann C.

Mol Pharmacol. 2009 Mar;75(3):534-41. doi: 10.1124/mol.108.052399. Epub 2008 Dec 23.

PMID:
19106230
15.

Dual role of the beta2-adrenergic receptor C terminus for the binding of beta-arrestin and receptor internalization.

Krasel C, Zabel U, Lorenz K, Reiner S, Al-Sabah S, Lohse MJ.

J Biol Chem. 2008 Nov 14;283(46):31840-8. doi: 10.1074/jbc.M806086200. Epub 2008 Sep 18.

16.

Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis.

Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A, Verbeuren TJ, Kumar H S A, Schmidt HH.

Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16671-6. Epub 2004 Nov 16.

17.

[Getting old among the unfamiliar].

Zabel U.

Pflege Aktuell. 2002 Oct;56(10):522-5. German. No abstract available.

PMID:
12402640
18.

Synaptic localization of nitric oxide synthase and soluble guanylyl cyclase in the hippocampus.

Burette A, Zabel U, Weinberg RJ, Schmidt HH, Valtschanoff JG.

J Neurosci. 2002 Oct 15;22(20):8961-70.

19.

Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide.

Zabel U, Kleinschnitz C, Oh P, Nedvetsky P, Smolenski A, Müller H, Kronich P, Kugler P, Walter U, Schnitzer JE, Schmidt HH.

Nat Cell Biol. 2002 Apr;4(4):307-11.

PMID:
11887187
20.

Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats.

Ruetten H, Zabel U, Linz W, Schmidt HH.

Circ Res. 1999 Sep 17;85(6):534-41.

PMID:
10488056
21.
22.

Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.

Galle J, Zabel U, Hübner U, Hatzelmann A, Wagner B, Wanner C, Schmidt HH.

Br J Pharmacol. 1999 May;127(1):195-203.

23.

Human soluble guanylate cyclase: functional expression and revised isoenzyme family.

Zabel U, Weeger M, La M, Schmidt HH.

Biochem J. 1998 Oct 1;335 ( Pt 1):51-7.

24.

Nic96p is required for nuclear pore formation and functionally interacts with a novel nucleoporin, Nup188p.

Zabel U, Doye V, Tekotte H, Wepf R, Grandi P, Hurt EC.

J Cell Biol. 1996 Jun;133(6):1141-52.

25.

Nuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleus.

Zabel U, Henkel T, Silva MS, Baeuerle PA.

EMBO J. 1993 Jan;12(1):201-11.

26.

Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-kappa B subunit.

Henkel T, Zabel U, van Zee K, Müller JM, Fanning E, Baeuerle PA.

Cell. 1992 Mar 20;68(6):1121-33.

PMID:
1547506
27.

Purified I kappa B-beta is inactivated upon dephosphorylation.

Link E, Kerr LD, Schreck R, Zabel U, Verma I, Baeuerle PA.

J Biol Chem. 1992 Jan 5;267(1):239-46.

28.
29.

[Premature return of the drivers' license--temporal limits according to section 69 a Abs. 7 StGB].

Zabel GE, Zabel U.

Blutalkohol. 1992 Jan;29(1):62-71. German.

PMID:
1558746
30.
31.
33.

Supplemental Content

Support Center